共同生活
发表于 2025-3-27 00:34:43
Federal Republic of Germany: Neuroleptic Relapse Preventionfrequent episodical relapses. Without neuroleptic therapy about 40%-70% of schizophrenic patients relapsed within 2 years following the first psychotic episode. In the FRG, these facts were the reason for changing from short-term neuroleptic therapy to long-term treatment. The aims of the long-term use of neuroleptics (NL) are:
entreat
发表于 2025-3-27 02:07:09
http://reply.papertrans.cn/40/3910/390959/390959_32.png
kidney
发表于 2025-3-27 05:25:24
http://reply.papertrans.cn/40/3910/390959/390959_33.png
Arresting
发表于 2025-3-27 12:02:36
Duration of Neuroleptic Maintenance Treatmentatients are to receive this maintenance treatment (see review by Johnson, this volume) as well as the question whether reliable predictors of the individual relapse risk are available (see review by Marder, this volume). Thus a certain amount of overlap with these other reviews cannot be avoided.
antidote
发表于 2025-3-27 13:39:47
http://reply.papertrans.cn/40/3910/390959/390959_35.png
Gullible
发表于 2025-3-27 19:30:17
Sweden: Neuroleptic Relapse PreventionSwedish psychiatry is sectorized. That usually means the total responsibility for all the various types of mental disorders lies within a catchment area. Within such a catchment area the in- and outpatient care is coordinated with the use of ward units as well as clinics.
ARBOR
发表于 2025-3-28 00:04:29
http://reply.papertrans.cn/40/3910/390959/390959_37.png
狂热语言
发表于 2025-3-28 05:37:26
http://reply.papertrans.cn/40/3910/390959/390959_38.png
paragon
发表于 2025-3-28 10:12:58
Austria: The Current Status of Maintenance Treatment in Schizophreniaut 20% of all acute hospital admissions, while the percentage of schizophrenics in long-stay units probably exceeds 30%. Twenty-nine neuroleptics of the various chemical classes are currently registered and marketed in Austria. Four of these (haloperidol, fluphenazine, flupenthixol and clopenthixol)
STALE
发表于 2025-3-28 12:45:08
United Kingdom: Neuroleptic Relapse Prevention(Davis 1975). Attempts to produce clear guidelines or recommendations for relapse prevention may currently be confounded by our scant knowledge regarding basic issues such as the relative value of oral and depot preparations in this regard; whether particular drugs, classes of drugs or dose regimes